Virility Medical News
12 articles
המנכ"לית שרוצה לטפל באחת הבעיות שהכי מטרידות גברים
Sharon Ravid has taken over as CEO of Virility Medical, a company that has developed a treatment for premature ejaculation. The company, which was established in 2016, is transitioning from product development and clinical trials to the commercial stage. Since its inception, Virility Medical has raised approximately $20 million. The companys product, In2, is already being sold in Israel and the UK, and the company plans to enter the US market in the future. Ravid sees Virility Medical as part of the emerging sex-tech world.
Management ChangesInvestment
Virility Medical introduces tech solution to premature ejaculation
Israeli startup Virility Medical has announced the launch of its device, in2, for the treatment of premature ejaculation in Israel, following a successful release in the UK. The device, which is drug-free and has undergone clinical testing, is said to extend the duration of sexual intercourse and enhance orgasm. It has been approved by regulatory bodies, including the FDA for marketing in the US, CE for marketing in Europe, and the Israeli Ministry of Health. The company was founded in 2016 and is led by CEO Sharon Ravid.
CustomersExpand
הושק בישראל: הגאדג'ט הישראלי שפותר את הבעיה שגברים לא אוהבים לדבר עליה
Startup With A Longer-Lasting Solution For Men Raises $10M
Israeli startup Virility Medical has raised $10 million for its skin patch designed to treat premature ejaculation. The Virility Patch uses EMS to prolong intercourse and enhance mens sexual performance. The company plans to make the patches available for purchase in the fall. Migdal Insurance is investing $8 million, and Arkin Holdings is investing $2 million in the startup. Virility Medical aims to provide a ground-breaking, effective, and simple solution to the estimated 79 million men suffering from premature ejaculation in the United States and the EU.
Investment
Electrical stimulation zaps premature ejaculation
Israeli startup Virility Medical has developed a non-pharmacological solution for premature ejaculation. The companys disposable vPatch, which delivers electric stimulation to inhibit orgasm, is the first of its kind. Virility conducted studies to determine that men would be willing to pay $15 per session for the product. The vPatch has received FDA and CE approvals and will be sold over the counter. Virility is planning a massive advertising campaign to target both men and women. The company has also raised $10 million in funding, including investments from Arkin Holdings and the Israel Innovation Authority. Virility is already working on a reusable version of the vPatch with a rechargeable battery and a Bluetooth-connected app for intensity control.
Customers
חברה ישראלית קיבלה אישור FDA לטיפול בבעיה שמציקה למיליוני גברים כלכליסט
Virility Medical, an Israeli company, has received approval from the US Food and Drug Administration (FDA) to market a patch for the treatment of premature ejaculation in the United States. The FDA approval comes after the company already received approval from European authorities to market the product in Europe. The company, which was established in 2016, has developed a non-drug patch that men stick on the skin, and at the required moment the patch produces an electrical stimulation that prevents premature ejaculation. The company plans to start marketing the patch in the second quarter of 2022, initially in Europe.
InvestmentCustomers
פיתוח ישראלי רוצה לפתור את אחת מהבעיות שהכי מציקות לגברים
Israeli startup Virility Medical has developed a medical sticker to help men with premature ejaculation. The sticker, which is applied to the skin, emits electrical signals that stimulate and control muscle contractions, delaying ejaculation. The company has received CE approval for marketing the sticker in the European Union. Virility Medical raised $8 million in funding, including $1.5 million from Almeda Ventures and Netcher, which will be used for FDA approval and preparing the product for sales in the US.
Investment
Premature ejaculation patch co Virility raising $8m
Israeli company Virility Medical is raising $8 million in a financing round led by Arkin Investments and with the participation of Almeda Ventures. The company is in the advanced clinical stage of developing a patch with neuromodulation capabilities for the treatment of premature ejaculation. The funding will be used to obtain FDA marketing approval. Almeda Ventures, whose partners include Tzahi Sultan, Dr. Irit Yaniv, and Amir Blatt, has a portfolio that includes BioProtect, TailorMed, Nurami Medical, and Lumen - Metaflow.
Investment
סטארט-אפ ישראלי מצא פתרון לבעיה של רבע מהגברים בעולם
Israeli startup Virility Medical has developed a medical solution for premature ejaculation, a problem that affects a quarter of men worldwide. The company has created a thin, flexible patch that is placed discreetly on the perineum before sexual activity. The patch can be controlled using a simple mobile application, which sends a low-intensity electrical stimulation to the muscle responsible for ejaculation, allowing users to delay ejaculation easily and effectively. The current solutions on the market mainly consist of devices, products, and prescription drugs, but they are not considered effective or safe. Virility Medical aims to capture a global market estimated at $2 billion and growing at a rate of 9% per year.
Customers
Premature Ejaculation: There's an App, and a Patch, For That
Israeli startup Virility Medical Ltd. has developed a single-use electrified skin patch and app to help men with premature ejaculation. The patch, when applied to the perineum, delivers neuromuscular stimulation to delay ejaculation. The intensity of the stimulation can be controlled through the app. Premature ejaculation is estimated to occur in 25% to 40% of adult men. The U.S. FDA has not yet approved any medications for its treatment. Ron Miron, former head of Teva Pharmaceutical Industries Israeli operation, has joined Virility as chairman. The company has launched a crowdfunding campaign and has received a $1 million grant from the Israel Innovation Authority. It has also raised an additional $850,000, with investment from Ron Zuckerman, founder of Sapiens International Corporation N.V.
InvestmentManagement Changes
Patch-and-app system prevents premature ejaculation
Israeli medical devices startup Virility Medical has completed a successful hospital-based trial for its high-tech solution for premature ejaculation. The company has developed a single-use disposable patch that is placed on the skin of the perineum before intercourse. Controlled by a smartphone application, the patch sends a low-frequency electrical current to delay ejaculation. The recent trial showed a significant increase in delaying ejaculation without any side effects. Virility Medical aims to tap into a market that is expected to reach $2 billion by 2020. The company has raised NIS 3 million (about $858,000) from investors and plans to embark on a second funding round.
Customers
Premature ejaculation treatment co Virility raises NIS 3m
Virility Medical, an Israeli company, has raised NIS 3 million for the development of an electrical stimulation patch for the treatment of premature ejaculation. The company aims to provide a more effective and convenient solution compared to existing treatments. Currently, there is only one approved drug for premature ejaculation, but it has severe side effects. The market potential for sexual medicine is significant, with millions of men actively seeking a solution. Virility Medical has conducted two successful clinical trials and is starting a third trial at the Rambam Health Care Campus. The company is optimistic about the future and plans to continue its rapid pace of development.
Investment
